Longboard PharmaceuticalsNASDAQ: LBPH

Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has granted Breakthrough Therapy designation for its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older. “We are thrilled to receive Breakthroug.

Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

As the market continues to witness a resurgence in small-cap investments, led by a jump in investor optimism and speculation, there's been a seemingly steady flow of capital back into traditionally riskier sectors.

Clinical-stage biopharmaceutical firm Longboard Pharmaceuticals (NASDAQ: LBPH ) got the new year off to the best start possible with a dramatic run. Earlier Tuesday morning, management disclosed positive topline data for its therapeutic bexicaserin, which addresses seizures in patients with developmental and epileptic encephalopathies (DEEs).

Longboard Pharmaceuticals Inc shares surged 181% to $16.96 in late-morning trading on Tuesday after the clinical-stage biopharmaceutical company revealed positive topline data from its PACIFIC Study evaluating bexicaserin, which reduced seizures by 53.3% across a population of patients with developmental and epileptic encephalopathies (DEE).  Longboard noted the phase 1b/2a study included 52 patients ages 12 to 65 years old with different seizure disorders, including Lennox-Gastaut syndrome and Dravet syndrome.

Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Longboard Pharmaceuticals, Inc. (LBPH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.